We commend Li *et al.*[@b1] for their article "Clinical characteristics of the patients with Hodgkin\'s lymphoma involving extranodal sites" (published in the *Chinese Journal of Cancer* in July 2012). We agree that in comparison with extranodal non-Hodgkin\'s lymphoma (NHL), the incidence of extranodal Hodgkin\'s lymphoma (HL) is much rarer and thus described much less frequently in the literature. We would like add a few points to complement the above mentioned article.

Patients with extranodal lymphoma (either NHL or HL) have a higher risk of being infected with the human immunodeficiency virus (HIV) than do those with lymphoma confined to the lymphoreticular system. As a corollary, HIV-infected patients who develop lymphomas are more likely to manifest extranodal disease compared with the non-HIV-infected population. Indeed, various series consistently showed that more than 50% of HIV-associated lymphomas present with extranodal disease[@b2]--[@b5].

HL patients with HIV infection, especially those carrying a high risk of extranodal involvement, are nearly always co-infected with the Epstein-Barr virus and often have other high risk features, such as (but not limited to) B symptoms, high stage at presentation, and poor outcome to standard therapy[@b3]--[@b5].

Bearing the above points in mind, we suggest that every patient with extranodal HL should be evaluated to assess the HIV status and also to ascertain the CD4^+^ T cell count. If done, the highly active anti-retroviral therapy could be initiated to improve CD4^+^ T cell counts, which in turn could improve patient survival by reducing the risk of infection-related deaths and indirectly improving patient tolerance for chemotherapy[@b6],[@b7].

Lastly, we also suggest the routine use of whole body 18-fluorodeoxyglucose positron emission tomography scan among all HIV-positive individuals who develop lymphomas to detect foci of extranodal involvement that would otherwise be missed.
